search

Active clinical trials for "Recurrence"

Results 741-750 of 3790

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Advanced Malignant NeoplasmMetastatic Malignant Neoplasm2 more

This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Active18 enrollment criteria

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With...

GliomaHematopoietic and Lymphoid Cell Neoplasm48 more

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Active43 enrollment criteria

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Grade 3a Follicular LymphomaRecurrent Grade 1 Follicular Lymphoma3 more

This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Active50 enrollment criteria

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Breast Cancer FemaleBreast Cancer7 more

The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.

Active25 enrollment criteria

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Accelerated Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive55 more

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.

Active66 enrollment criteria

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent...

EGFR Gene AmplificationEGFR Gene Mutation4 more

This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in tumor glucose utilization, which may allow investigators to obtain an early read out on the impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.

Active46 enrollment criteria

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer...

Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine Carcinoma10 more

This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and temozolomide may work better in treating patients with small-cell lung cancer and neuroendocrine cancer.

Active44 enrollment criteria

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

ALK Gene MutationBRAF Gene Mutation10 more

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.

Active52 enrollment criteria

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian,...

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma1 more

This phase I trial studies the side effects of genetically modified T cells and decitabine in treating patients with recurrent or refractory epithelial or non-epithelial ovarian, primary peritoneal, or fallopian tube cancer that has come back or has not responded to previous treatments. White blood cells called T cells are collected via a process called leukapheresis, genetically modified to recognize and attack tumor cells, then given back to the patient. Decitabine may induce and increase the amount of the target protein NY-ESO-1 available on the surface of tumor cells. Giving genetically modified T cells and decitabine may kill more tumor cells.

Active33 enrollment criteria

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Appendix AdenocarcinomaHuman Papillomavirus-Related Anal Squamous Cell Carcinoma20 more

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Active107 enrollment criteria
1...747576...379

Need Help? Contact our team!


We'll reach out to this number within 24 hrs